Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
22.27
+1.10 (+5.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anaptysbio Inc
< Previous
1
2
3
4
Next >
Anaptys Announces Participation in November and December Investor Conferences
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 30, 2024
Via
Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
October 21, 2024
Via
Benzinga
What Analysts Are Saying About AnaptysBio Stock
September 26, 2024
Via
Benzinga
Insiders Buying Yum China And 2 Other Stocks
August 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
Anaptys Announces Participation in September Investor Conferences
August 29, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Why AnaptysBio Was Such a Healthy Stock This Week
August 23, 2024
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
Via
The Motley Fool
4 Analysts Assess AnaptysBio: What You Need To Know
August 06, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On AnaptysBio
May 10, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On AnaptysBio
April 01, 2024
Via
Benzinga
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
August 14, 2024
Via
Benzinga
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Via
Investor's Business Daily
S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday
August 14, 2024
US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and small caps outperform.
Via
Benzinga
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 14, 2024
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
From
AnaptysBio, Inc.
Via
GlobeNewswire
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
August 05, 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.
Via
Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Via
InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
April 12, 2024
A powerfully bullish new analyst take on the company helped it rally on the market.
Via
The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
March 12, 2024
AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseeing stock surge amid clinical milestones. Analysis compares PD-1 agonist...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.